Registro Completo
|
Biblioteca(s): |
Embrapa Unidades Centrais. |
|
Data corrente: |
24/05/2018 |
|
Data da última atualização: |
24/05/2018 |
|
Autoria: |
LIGUORI, T. T. A.; MELCHERT, A.; TAKAHIRA, R. K.; RAMOS, P. R. R.; RODOVANI, C. R.; BARRETTI, P.; GUIMARÃES-OKAMOTO, P. T. C. |
|
Afiliação: |
Tácia T. A. Liguori, Departamento de Clínica Veterinária/FMVZ/Universidade Estadual Paulista - Unesp; Alessandra Melchert, Departamento de Clínica Veterinária/FMVZ/Universidade Estadual Paulista - Unesp; Regina K. Takahira, Departamento de Clínica Veterinária/FMVZ/Universidade Estadual Paulista - Unesp; Paulo R. R. Ramos, Departamento de Bioestatística, Faculdade de Biociências, Universidade Estadual Paulista - Unesp; Carlos R. Padovani, Departamento de Bioestatística, Faculdade de Biociências, Universidade Estadual Paulista - Unesp; Pasqual Barretti, Departamento de Medicina Interna, Faculdade de Medicina, Universidade Estadual Paulista - Unesp; Priscylla T. C. Guimarães-Okamoto, Departamento de Clínica Veterinária/FMVZ/Universidade Estadual Paulista - Unesp. |
|
Título: |
Randomized controlled clinical trial of ketoanalogues supplementation in dogs with chronic kidney disease. |
|
Ano de publicação: |
2018 |
|
Fonte/Imprenta: |
Pesquisa Veterinária Brasileira, Rio de Janeiro, v. 38, n. 3, p. 489-495, março 2018 |
|
Idioma: |
Inglês |
|
Notas: |
Título em português: Estudo clínico randomizado controlado da suplementação de cetoanálogos em cães com doença renal crônica. |
|
Conteúdo: |
The objective was to verify the effectiveness of ketoanalogues in dogs with Chronic Kidney Disease (CKD) stage 3. Controlled randomized clinical trial was performed with twenty dogs with CKD stage 3. Animals were subjected to: Group 1 (control): conventional therapy (CT) for CKD; Group 2: CT and 60mg/kg, OA, q48h of keto-supplementa; Group 3, CT and 60mg/kg, OA, q24h of keto-supplementa; and Group 4, CT and 120mg/kg, OA, q12h of keto-supplementa. All dogs received canine renal diet. Animals were evaluated at the beginning of therapy and after 15 and 30 days. Complete blood count (CBC), serum urea, creatinine, phosphorus, calcium, potassium and sodium and urine protein/creatinine (UPC) ratio were analyzed. The use of ketoanalogues in dogs with CKD stage 3 during the period of 30 days showed no efficacy, in any of the studies dosages, to improve signs and symptoms of the disease, improve the values of CBC, reduce serum urea and creatinine, normalize electrolytes or reduce UPC. It is concluded that the use of ketoanalogues does not impact the clinical outcomes in dogs with CKD stage 3. |
|
Palavras-Chave: |
Aminoácido essencial; Canino; Cetoanálogos; Clínica; Clinics; Doença renal crônica. |
|
Thesagro: |
Cão; Suplemento Alimentar. |
|
Thesaurus NAL: |
Dietary supplements; Dogs; Essential amino acids. |
|
Categoria do assunto: |
-- |
|
URL: |
https://ainfo.cnptia.embrapa.br/digital/bitstream/item/177611/1/Randomized-controlled-clinical-trial-of-ketoanalogues.pdf
|
|
Marc: |
LEADER 02224naa a2200337 a 4500
001 2091909
005 2018-05-24
008 2018 bl uuuu u00u1 u #d
100 1 $aLIGUORI, T. T. A.
245 $aRandomized controlled clinical trial of ketoanalogues supplementation in dogs with chronic kidney disease.$h[electronic resource]
260 $c2018
500 $aTítulo em português: Estudo clínico randomizado controlado da suplementação de cetoanálogos em cães com doença renal crônica.
520 $aThe objective was to verify the effectiveness of ketoanalogues in dogs with Chronic Kidney Disease (CKD) stage 3. Controlled randomized clinical trial was performed with twenty dogs with CKD stage 3. Animals were subjected to: Group 1 (control): conventional therapy (CT) for CKD; Group 2: CT and 60mg/kg, OA, q48h of keto-supplementa; Group 3, CT and 60mg/kg, OA, q24h of keto-supplementa; and Group 4, CT and 120mg/kg, OA, q12h of keto-supplementa. All dogs received canine renal diet. Animals were evaluated at the beginning of therapy and after 15 and 30 days. Complete blood count (CBC), serum urea, creatinine, phosphorus, calcium, potassium and sodium and urine protein/creatinine (UPC) ratio were analyzed. The use of ketoanalogues in dogs with CKD stage 3 during the period of 30 days showed no efficacy, in any of the studies dosages, to improve signs and symptoms of the disease, improve the values of CBC, reduce serum urea and creatinine, normalize electrolytes or reduce UPC. It is concluded that the use of ketoanalogues does not impact the clinical outcomes in dogs with CKD stage 3.
650 $aDietary supplements
650 $aDogs
650 $aEssential amino acids
650 $aCão
650 $aSuplemento Alimentar
653 $aAminoácido essencial
653 $aCanino
653 $aCetoanálogos
653 $aClínica
653 $aClinics
653 $aDoença renal crônica
700 1 $aMELCHERT, A.
700 1 $aTAKAHIRA, R. K.
700 1 $aRAMOS, P. R. R.
700 1 $aRODOVANI, C. R.
700 1 $aBARRETTI, P.
700 1 $aGUIMARÃES-OKAMOTO, P. T. C.
773 $tPesquisa Veterinária Brasileira, Rio de Janeiro$gv. 38, n. 3, p. 489-495, março 2018
Download
Esconder MarcMostrar Marc Completo |
|
Registro original: |
Embrapa Unidades Centrais (AI-SEDE) |
|
